Dr. Oscar Streeter Named Medical Director for the Cancer Center at San Joaquin Community Hospital
Oscar E. Streeter, Jr., MD, F.A.C.R.O has been named the medical director for The Cancer Center at San Joaquin Community Hospital (SJCH).
Dr. Streeter will join The Cancer Center team this fall in preparation for the facility’s opening in late 2012. He is currently a professor and the chair of Department of Radiation Oncology at Howard University College of Medicine in Washington, D.C.
“We are thrilled to welcome Dr. Streeter to The Cancer Center at SJCH,” said Jarrod McNaughton, SJCH’s vice president of marketing and development. “His experience and expertise in radiation oncology raises the bar in cancer treatment for our community.”
Dr. Streeter received a Bachelor’s of Science degree in biology from the University of Southern California (USC) in 1978, where he played varsity water polo and was co-captain of the team in 1976.
He received his Doctor of Medicine degree from Howard University College of Medicine in 1982 and completed a residency in radiation oncology at Howard University Hospital from1983 to 1986.
In July 1986, Dr. Streeter started his own practice with Southern California Kaiser Permanente Hospital in Los Angeles. By 1990, he joined the faculty of USC in 1990 as the Chief of Service and Residency Program Director over the next 18 years, before joining the staff at Howard in July 2008.
Dr. Streeter is also a former chair of the National Black Leadership on Cancer for the Greater Los Angeles area; Board Chair of the Stennis Foundation to prevent and treat colorectal cancer; and principal investigator for the Radiation Therapy Oncology Group (RTOG) studies at USC and now at Howard.
His most recent research is in high-dose rate brachytherapy to local regional sites and situations including breast, prostate, recurrent colorectal, esophagus, lung carcinomas and sarcomas. Dr. Streeter also has a major interest of his is the role of socioeconomic factors and how they affect access to quality care. Dr. Streeter has shown throughout his career - and in his writings - that participation by patients in clinical trials not only leads to future advances, but it provides a framework for value-based clinical care that benefits current patients.